Alzheimer’s drug pipeline hits record high, raising hopes for treatment and prevention
London: A decade of rapid growth in Alzheimer’s research is “reshaping what the future could hold for people living with the disease,” according to a new review of emerging treatments published Tuesday.
The study found that the number of potential new drugs for Alzheimer’s has surged by 40% in ten years. Researchers are now testing drugs that could help people at every stage of Alzheimer’s — from those who have no symptoms but are at risk, to those in the later, more severe stages.
“The 2026 pipeline review gives me huge optimism that we’re building towards a future in which Alzheimer’s can be effectively treated — and, in time, prevented,” said lead researcher Dr. Jeffrey Cummings from the University of Nevada, Las Vegas.
The review tracks clinical trials worldwide and notes a shift from focusing only on late-stage disease to targeting early biological changes. New approaches include anti-amyloid and anti-tau therapies, drugs that reduce inflammation, and treatments aimed at vascular and metabolic factors.
Alzheimer’s Research UK welcomed the findings. “The Alzheimer’s drug pipeline is now the largest and most diverse it has ever been, and that breadth increases the chances of finding treatments people urgently need,” said Dr. Sheona Scales, the charity’s director of research.
More than 55 million people live with dementia globally, with Alzheimer’s causing 60–70% of cases. Two disease-modifying drugs have been approved in the US and UK since 2023, but access remains limited and benefits are modest.
